Latest stories

  • in

    Combination therapy with oral fluvoxamine and inhaled budesonide significantly Cuts Severe Disease in COVID-19

    Researchers have found in a randomized controlled trial that treatment with oral antidepressant fluvoxamine plus inhaled budesonide among high-risk outpatients with early COVID-19 reduced the incidence of severe disease requiring advanced care. Previous studies evaluated these drugs independently. The combined effect seems to offer benefits over individual use of each drug. The findings are published […] More

  • in

    USFDA nod to Roche’s Polivy in combination with R-CHP for certain types of previously untreated diffuse large B-cell lymphoma

    Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an […] More

  • in

    Acetaminophen-Ibuprofen Combination In Managing Dental Pain: Review

    The most prevalent cause of oral pain is toothache. Fractured teeth, exposed dentin, and untreated dental decay- are among the most commonly reported causes of toothache. With a high toothache prevalence ranging from 5% to 88% across nations and populations, dental pain is now recognized as a public health issue. Alarmingly, research reveals that one […] More

  • in

    Countering Post-operative Wound Inflammation with Trypsin-Bromelain-Rutoside Combination

    Countering Post-operative Wound Inflammation with Trypsin-Bromelain-Rutoside Combination

    It has been well established that Systemic enzyme therapy (SET) aids better and faster healing when compared to usual anti-inflammatory drugs like non-steroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics. Recently, SET with trypsin (serine protease), bromelain (cysteine protease) and rutoside (bioflavinoid) combination have gained popularity as a treatment for pain and inflammation.[1] Given the above […] More

  • in

    Sun Pharma gets CDSCO panel nod to study COPD drug combination

    New Delhi: Pharmaceutical major, Sun Pharma has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the active Post-marketing Surveillance (PMS) Study of the fixed-dose combination drug Fluticasone Furoate 200mcg plus Vilanterol 25mcg powder for inhalation. However, this approval is subject to conditions that […] More

  • in

    Merck gets USFDA nod for Keytruda in combination with Padcev to treat Advanced or Metastatic Urothelial Cancer

    Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy. This […] More

  • in

    Conduct PK study for repeated dose and Phase III CT : CDSCO Panel tells Sun Pharma on Psoriatic drug combination

    New Delhi: Rejecting the drug major Sun Pharma’s proposal for a Phase III clinical trial study waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined that the firm should conduct the pharmacokinetic (PK) study for repeated dose and the Phase III clinical trial of the fixed-dose combination […] More